Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Novartis AG before investing.

In this article, we go over a few key elements for understanding Novartis AG’s stock price such as:

• Novartis AG’s current stock price and volume
• Why Novartis AG’s stock price changed recently
• Upgrades and downgrades for NVS from analysts
• NVS’s stock price momentum as measured by its relative strength

About Novartis AG (NVS)

Before we jump into Novartis AG’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD). It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in the chronic and/or accelerated phase; Xolair for the treatment of allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Still’s disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and other types of functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma for the treatment of genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran), a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.

Want to learn more about Novartis AG’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Novartis AG.

Novartis AG’s Stock Price as of Market Close

As of September 14, 2026, 4:00 PM, CST, Novartis AG’s stock price was $138.990.

Novartis AG is up 1.33% from its previous closing price of $137.160.

During the last market session, Novartis AG’s stock traded between $138.990 and $141.640. Currently, there are approximately 1,905.00 million shares outstanding for Novartis AG.

Novartis AG’s price-earnings (P/E) ratio is currently at 20.7, which is high compared to the Pharmaceuticals industry median of 17. The price-earnings ratio gauges market expectation of future performance by relating a stock’s current share price to its earnings per share.

Novartis AG Stock Price History

Novartis AG’s (NVS) price is currently down 8.6% so far this month.

During the month of September, Novartis AG’s stock price has reached a high of $164.480 and a low of $137.000.

Over the last year, Novartis AG has hit prices as high as $170.460 and as low as $121.570. Year to date, Novartis AG’s stock is up 0.81%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Novartis AG Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of September 11, 2026, there was 1 analyst who downgraded Novartis AG’s stock and 0 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Novartis AG’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Novartis AG’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Novartis AG’s current valuation based on AAII’s Value Grade is a D, which means it is considered to be Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Novartis AG (NVS) by visiting AAII Stock Evaluator.

Relative Price Strength of Novartis AG

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of September 11, 2026, Novartis AG has a weighted four-quarter relative price strength of -3.46%, which translates to a Momentum Score of 43 and is considered to be Average.

Want to learn more about how Novartis AG is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Novartis AG Stock Price: Bottom Line

As of September 14, 2026, Novartis AG’s stock price is $138.990, which is up 1.33% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Novartis AG stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.